[go: up one dir, main page]

PE20060301A1 - DERIVADOS PIRROLOPIRIDINAS COMO ANTAGONISTAS DE CRTh2 - Google Patents

DERIVADOS PIRROLOPIRIDINAS COMO ANTAGONISTAS DE CRTh2

Info

Publication number
PE20060301A1
PE20060301A1 PE2005000686A PE2005000686A PE20060301A1 PE 20060301 A1 PE20060301 A1 PE 20060301A1 PE 2005000686 A PE2005000686 A PE 2005000686A PE 2005000686 A PE2005000686 A PE 2005000686A PE 20060301 A1 PE20060301 A1 PE 20060301A1
Authority
PE
Peru
Prior art keywords
alkyl
methyl
pyridin
benzyl
halogen
Prior art date
Application number
PE2005000686A
Other languages
English (en)
Inventor
Kamlesh Jagdis Bala
Catherine Leblanc
Katharine Louise Turner
Brian Cox
Lyndon Nigel Brown
Simon James Watson
David Andrew Sandham
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0413619A external-priority patent/GB0413619D0/en
Priority claimed from GB0507693A external-priority patent/GB0507693D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20060301A1 publication Critical patent/PE20060301A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE LA FORMULA I, DONDE Q ES UN ENLACE, ALQUILENO C1-C10 SUSTITUIDO O NO POR HALOGENO; R1 Y R2 SON CADA UNO H, HALOGENO, ALQUILO C1-C8, ENTRE OTROS; R3 ES H, ALQUILO C1-C8, CARBOCICLO C3-C15, HALOALQUILO C1-C8, ENTRE OTROS; R4 Y R5 SON CADA UNO HALOGENO, ALQUILO C1-C8, HALOALQUILO C1-C8, ENTRE OTROS; R6 ES H, ALQUILO C1-C8; W ES CARBOCICLICO AROMATICO DE C6-C15, HETEROCICLICO DE 4-10 MIEMBROS CON AL MENOS UN HETEROATOMO SELECCIONADO DE N, O, S; X ES -SO2-, -CH2-, -CON- (ALQUILO C1-C8), ENTRE OTROS; m Y n SON CADA UNO 0-3; p ES 1. SON COMPUESTOS PREFERIDOS: ACIDO (1-BENCIL-2-METIL-1H-PIRROLO-[2,3-b]-PIRIDIN-3-IL)-ACETICO; [1-(3,4-DICLORO-BENCIL)-2-METIL-1H-PIRROLO-[2,3-b]-PIRIDIN-3-IL)-ACETICO; ACIDO [2-METIL-1-(2-METIL-BENCIL)-1H-PIRROLO-[2,3-b]-PIRIDIN-3-IL]-ACETICO. SE REFIERE TAMBIEN A UN PROCESO DE PREPARACION. DICHOS COMPUESTOS SON ANTAGONISTAS DE LA CRTh2 RECEPTORA QUIMIOATRAYENTE ACOPLADA CON PROTEINA-G SIENDO UTILES EN EL TRATAMIENTO DE CONDICIONES ALERGICAS, INFLAMATORIAS TALES COMO ASMA, PSORIASIS, CONJUNTIVITIS, ANEMIA APLASICA, ENTRE OTROS
PE2005000686A 2004-06-17 2005-06-15 DERIVADOS PIRROLOPIRIDINAS COMO ANTAGONISTAS DE CRTh2 PE20060301A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0413619A GB0413619D0 (en) 2004-06-17 2004-06-17 Organic compounds
GB0507693A GB0507693D0 (en) 2005-04-15 2005-04-15 Organic compounds

Publications (1)

Publication Number Publication Date
PE20060301A1 true PE20060301A1 (es) 2006-05-18

Family

ID=35510318

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000686A PE20060301A1 (es) 2004-06-17 2005-06-15 DERIVADOS PIRROLOPIRIDINAS COMO ANTAGONISTAS DE CRTh2

Country Status (28)

Country Link
US (5) US7666878B2 (es)
EP (1) EP1761529B3 (es)
JP (1) JP4886680B2 (es)
KR (1) KR101183330B1 (es)
AR (1) AR049443A1 (es)
AT (1) ATE378338T1 (es)
AU (1) AU2005254681B2 (es)
BR (1) BRPI0512060B8 (es)
CA (1) CA2569125C (es)
CY (1) CY1107851T1 (es)
DE (1) DE602005003365T3 (es)
DK (1) DK1761529T3 (es)
EC (1) ECSP067077A (es)
ES (1) ES2294717T7 (es)
HR (1) HRP20080022T4 (es)
IL (1) IL179604A (es)
MA (1) MA28666B1 (es)
MX (1) MXPA06014694A (es)
MY (1) MY144903A (es)
NO (1) NO338319B1 (es)
NZ (1) NZ551439A (es)
PE (1) PE20060301A1 (es)
PL (1) PL1761529T6 (es)
PT (1) PT1761529E (es)
RS (1) RS50552B (es)
RU (1) RU2379309C2 (es)
TW (1) TWI352702B (es)
WO (1) WO2005123731A2 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds
KR101472248B1 (ko) 2006-02-10 2014-12-16 서미트 코포레이션 피엘씨 뒤시엔느 근이영양증의 치료
GB0611695D0 (en) * 2006-06-13 2006-07-26 Novartis Ag Organic compounds
KR101411820B1 (ko) 2006-08-07 2014-06-24 액테리온 파마슈티칼 리미티드 (3-아미노-1,2,3,4-테트라하이드로-9ｈ-카르바졸-9-일)-아세트산 유도체
RS55735B1 (sr) * 2007-08-03 2017-07-31 Summit (Oxford) Ltd Kombinacije lekova za lečenje dišenove mišićne distrofije
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
EP2268281A4 (en) * 2008-02-15 2012-05-02 Abbott Lab THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS
DK2318007T3 (da) * 2008-08-15 2013-03-25 N30 Pharmaceuticals Inc Nye pyrrol-inhibitorer af s-nitrosoglutathion-reduktase som terapeutiske midler
JP5524209B2 (ja) 2008-08-15 2014-06-18 エヌサーティー・ファーマシューティカルズ・インコーポレーテッド Ｓ−ニトロソグルタチオンレダクターゼのピロール阻害剤
DK2315591T3 (en) 2008-08-15 2016-06-06 Nivalis Therapeutics Inc NOVEL PYRROLE INHIBITORS OF S-nitrosoglutathione-reductase as therapeutic agents
EP2558447B1 (en) 2010-03-22 2014-09-17 Actelion Pharmaceuticals Ltd. 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
WO2012087861A1 (en) * 2010-12-23 2012-06-28 Merck Sharp & Dohme Corp. Quinoxalines and aza-quinoxalines as crth2 receptor modulators
CA2830204C (en) 2011-04-14 2019-04-09 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
TW201326151A (zh) 2011-10-25 2013-07-01 Shionogi & Co 具有ｐｇｄ２受體拮抗活性之雜環衍生物
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
EA030159B1 (ru) 2014-03-17 2018-06-29 Идорсиа Фармасьютиклз Лтд Производные азаиндолуксусной кислоты и их применение в качестве модуляторов рецепторов простагландина d2
JP6484644B2 (ja) 2014-03-18 2019-03-13 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ アザインドール酢酸誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
CA2957046C (en) 2014-08-04 2022-11-15 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US20180021302A1 (en) 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
KR20180033235A (ko) 2015-07-23 2018-04-02 머크 샤프 앤드 돔 코포레이션 Crth2 수용체 길항제에 대한 반응과 연관된 유전자 마커
UA123156C2 (uk) 2015-09-15 2021-02-24 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА ФОРМА (S)-2-(8-((5-ХЛОРПІРИМІДИН-2-ІЛ)(МЕТИЛ)АМІНО)-2-ФТОР-6,7,8,9-ТЕТРАГІДРО-5H-ПІРИДО[3,2-b]ІНДОЛ-5-ІЛ)ОЦТОВОЇ КИСЛОТИ, ЇЇ ЗАСТОСУВАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ
US10457627B2 (en) 2015-09-23 2019-10-29 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
RU2744976C1 (ru) * 2015-09-29 2021-03-17 Новартис Аг Способ получения 1-(4-метансульфонил-2-трифторметилбензил)-2-метил-1н-пирроло[2,3-b]пиридин-3-ил-уксусной кислоты
WO2017210261A1 (en) * 2016-05-31 2017-12-07 Concert Pharmaceuticals, Inc. Deuterated fevipiprant
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
BR112018075734A2 (pt) 2016-06-13 2019-04-02 Gilead Sciences, Inc. composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
CN106188040B (zh) * 2016-06-28 2018-03-23 浙江宏鑫染化材料有限公司 一种Fevipiprant及其中间体的制备方法
EP3489235A4 (en) 2016-07-21 2020-01-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compound as crth2 inhibitor
ES2927019T3 (es) 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
JP6991239B2 (ja) 2017-03-30 2022-01-12 エックスダブリューファルマ リミテッド 二環式ヘテロアリール誘導体ならびにその調製および使用
JOP20190223A1 (ar) * 2017-04-01 2019-09-26 Novartis Ag عملية لتحضير حمض 1-(4- ميثان سلفونيل -2- تراي فلورو ميثيل - بنزيل)-2- ميثيل -1h- بيرولو [2، 3-b] بيريدين -3- يل- أسيتيك
PH12019502776A1 (en) 2017-06-30 2020-10-26 Univ California Compositions and methods for modulating hair growth
WO2019011337A1 (zh) * 2017-07-14 2019-01-17 苏州科睿思制药有限公司 Qaw-039的晶型及其制备方法和用途
WO2019130166A1 (en) * 2017-12-26 2019-07-04 Mankind Pharma Ltd. Preparation of 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoro methyl)phenyl]methyl] pyrrolo[2,3-b]pyridin-3-yl]acetic acid
JP7296970B2 (ja) 2018-01-19 2023-06-23 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド インドール誘導体の結晶形とその調製方法および使用
CN110467612B (zh) * 2018-05-09 2020-09-25 新发药业有限公司 一种前列腺素d2受体抑制剂化合物的简便制备方法
WO2020062251A1 (en) 2018-09-30 2020-04-02 Xw Laboratories, Inc. Compounds as neuronal histamine receptor-3 antagonists and uses thereof
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
WO2021124277A1 (en) 2019-12-20 2021-06-24 Nuevolution A/S Compounds active towards nuclear receptors
EP4077262B1 (en) 2019-12-20 2024-07-24 XWPharma Ltd. Methods of synthesizing 4-valyloxybutyric acid
AU2021249530A1 (en) 2020-03-31 2022-12-01 Nuevolution A/S Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
EP4167966A1 (en) 2020-06-18 2023-04-26 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
CN116261451A (zh) 2020-07-24 2023-06-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的药物组合物和药物动力学
US11395801B2 (en) 2020-10-05 2022-07-26 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
US11510892B2 (en) 2021-03-19 2022-11-29 XWPharma Ltd. Pharmacokinetics of combined release formulations of a γ-hydroxybutyric acid derivative
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320268A (en) * 1964-08-14 1967-05-16 Merck & Co Inc 1-aroyl or heteroaroyl-7-azaindole-3-carboxylates and derivatives
US5212195A (en) * 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
GB9319297D0 (en) 1993-09-17 1993-11-03 Wellcome Found Indole derivatives
JPH10510510A (ja) 1994-06-09 1998-10-13 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗物質
EP0765327B1 (en) * 1994-06-16 1999-07-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
TWI262920B (en) 2000-10-27 2006-10-01 Elbion Ag New 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them
US7153852B2 (en) 2001-09-07 2006-12-26 Ono Pharmaceutical Co., Ltd. Indole compounds, process for producing the same and drugs containing the same as the active ingredient
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
US7534897B2 (en) 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
SE0201635D0 (sv) * 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
DE602005003365D1 (de) 2011-01-05
IL179604A0 (en) 2007-05-15
NO338319B1 (no) 2016-08-08
HK1103730A1 (en) 2007-12-28
DK1761529T3 (da) 2008-03-25
NO20070323L (no) 2007-03-12
WO2005123731A2 (en) 2005-12-29
CA2569125C (en) 2013-01-08
HRP20080022T3 (en) 2008-02-29
ES2294717T7 (es) 2012-06-14
BRPI0512060B8 (pt) 2021-05-25
HRP20080022T4 (hr) 2011-10-31
KR101183330B1 (ko) 2012-09-17
ECSP067077A (es) 2007-01-26
DE602005003365T2 (de) 2008-09-11
MA28666B1 (fr) 2007-06-01
PL1761529T3 (pl) 2008-04-30
US20100204225A1 (en) 2010-08-12
US20130267518A1 (en) 2013-10-10
RS50552B (sr) 2010-05-07
KR20070032694A (ko) 2007-03-22
WO2005123731A3 (en) 2006-05-04
US7666878B2 (en) 2010-02-23
JP2008502638A (ja) 2008-01-31
CY1107851T1 (el) 2013-06-19
JP4886680B2 (ja) 2012-02-29
EP1761529B1 (en) 2007-11-14
MXPA06014694A (es) 2007-02-12
ATE378338T1 (de) 2007-11-15
US20080114022A1 (en) 2008-05-15
PT1761529E (pt) 2008-02-11
NZ551439A (en) 2009-09-25
US20100210610A1 (en) 2010-08-19
MY144903A (en) 2011-11-30
AU2005254681B2 (en) 2009-01-29
DE602005003365T3 (de) 2012-08-30
US8791256B2 (en) 2014-07-29
RU2007101277A (ru) 2008-07-27
AU2005254681A1 (en) 2005-12-29
US8470848B2 (en) 2013-06-25
ES2294717T3 (es) 2008-04-01
US8455645B2 (en) 2013-06-04
PL1761529T6 (pl) 2011-11-30
EP1761529B3 (en) 2011-06-15
TW200617009A (en) 2006-06-01
AR049443A1 (es) 2006-08-02
TWI352702B (en) 2011-11-21
EP1761529A2 (en) 2007-03-14
BRPI0512060A (pt) 2008-02-06
CA2569125A1 (en) 2005-12-29
US20140309254A1 (en) 2014-10-16
US9169251B2 (en) 2015-10-27
BRPI0512060B1 (pt) 2018-08-07
RU2379309C2 (ru) 2010-01-20
IL179604A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
PE20060301A1 (es) DERIVADOS PIRROLOPIRIDINAS COMO ANTAGONISTAS DE CRTh2
PE20080839A1 (es) Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
PE20091884A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparacion, asi como su uso como medicamento
BRPI0406762A (pt) Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça
AR075084A1 (es) Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
DK1696919T3 (da) 3-cycloalkylaminopyrrolidin-derivater som modulatorer af chemokinreceptorer
HU0400405D0 (en) Novel compounds
DE602005008558D1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
PE20081164A1 (es) Nuevos compuestos 521
PE20121148A1 (es) Compuestos heterociclicos y usos de los mismos
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
DE60214990D1 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
TN2009000112A1 (fr) Derives de sulfonamides servant d'agonistes adrenergiques et d'antagonistes muscariniques
PE20061088A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a
PE20110703A1 (es) Acidos naftilaceticos
PE20060878A1 (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
EA200500172A1 (ru) Азабициклопроизводные в качестве антагонистов мускариновых рецепторов
WO2008078762A1 (ja) ウレア構造を有する新規ｎ－(２－アミノフェニル)ベンズアミド誘導体
PE20060483A1 (es) Compuestos heterociclicos como antagonistas de nk1
PE20120810A1 (es) Compuestos derivados de 5-ciano-2-(feniltio)bencensulfonamida como antagonistas de ccr3
WO2007107373A1 (en) Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
ATE529181T1 (de) Neuartiges dispersionsmittel und zusammensetzungen daraus
PE20120811A1 (es) Antagonistas ccr3 arilsulfonamida
TW200606153A (en) Process for producing pyridine derivatives of Nk-1 receptor antagonist

Legal Events

Date Code Title Description
FG Grant, registration